Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Laura J. Esserman(University of California, San Francisco), Linda S. Lindström(Uppsala University)

JAMA Oncology

June 29, 2017

10.1001/jamaoncol.2017.1261

Cited by 129

Related Papers

Whole-genome analysis informs breast cancer response to aromatase inhibition

|Nature|2012|1k

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

|JAMA Oncology|2020|707

Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

|Radiology|2012|487

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

|Journal of Clinical Oncology|2017|411

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

|Cancer Cell|2022|335